NASDAQ:ASND

Ascendis Pharma A/s Stock Forecast

etoro logo Buy ASND
*Your capital is at risk
$255.62
+0.210 (+0.0822%)
At Close: Aug 10, 2026

Should you buy ASND stock?

Last updated:

Based on market data through , StockInvest.us rates Ascendis Pharma A/S (ASND) as a Sell Candidate with a technical score of -2.73 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation.

  • Sell signal since
  • Price since signal Up 2.31%
  • 3-month trend forecast Up 12.41%
  • Sell Candidate -2.73
AI Analysis AI Analysis of ASND AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add ASND to Watchlist?
Some Reasons Why To Add ASND:
  • High gross margin of 88.2%
  • Low bankruptcy risk (Altman Z-Score: 4.40)
  • Bullish trend confirmed on both short and long timeframes
PDF

Ascendis Pharma A/S stock price up 0.0822% on Monday
(Market data through Aug 10, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Sell candidate since Aug 06, 2026 Gain 2.31%

The Ascendis Pharma A/S stock price gained 0.0822% on the last trading day (Monday, 10th Aug 2026), rising from $255.41 to $255.62. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 2.73% from a day low at $250.87 to a day high of $257.73. The price has been going up and down for this period, and there has been a 0.87% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 100 thousand more shares were traded than the day before. In total, 423 thousand shares were bought and sold for approximately $108.25 million.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 12.41% during the next 3 months and, with a 90% probability hold a price between $256.25 and $324.90 at the end of this 3-month period.

ASND Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, August 03, 2026, and so far it has risen 5.00%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Ascendis Pharma A/S stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $256.89. On a fall, the stock will find some support from the short-term average at $248.15. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Support, Risk & Stop-loss for Ascendis Pharma A/S stock

On the downside, the stock finds support just below today's level from accumulated volume at $230.83 and $224.11. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Ascendis Pharma A/S finds support just below today's level at $230.83. If this is broken, then the next support from accumulated volume will be at $224.11 and $205.81.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $6.86 between high and low, or 2.73%. For the last week, the stock has had daily average volatility of 3.04%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ASND) For The Upcoming Trading Day Of Tuesday 11th

For the upcoming trading day on Tuesday, 11th we expect Ascendis Pharma A/S to open at $254.74, and during the day (based on 14 day Average True Range), to move between $251.60 and $259.64, which gives a possible trading interval of +/-$8.03 (+/-3.19%) up or down from last closing price. If Ascendis Pharma A/S takes out the full calculated possible swing range there will be an estimated 3.19% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $260.75 (2.01%) than the support at $230.83 (9.70%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Earnings coming up

Ascendis Pharma A/S will release earnings BMO on Thursday, August 13, 2026.The consensus among the analysts for the expected earnings (EPS) is $1.71. We will update the financials statements for Ascendis Pharma A/S, that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 4.93% in the first trading day after earnings release.

Is Ascendis Pharma A/S stock A Buy?

Ascendis Pharma A/S holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.725 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on August 11, 2026 - $254.74 ( 0.344%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

ASND Performance

Trading levels for ASND

StockInvest.us
Full Access. No Commitment. Up to 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 261.60 2.34%
R2 258.98 1.31%
R1 257.36 0.681%
Price 255.62
S1 252.12 -1.37%
S2 250.50 -2.00%
S3 247.88 -3.03%

Accumulated Volume Support & Resistance Levels

Level Price
R3 277.18 8.43%
R2 261.58 2.33%
R1 260.75 2.01%
Price 255.62
S1 230.83 -9.70%
S2 224.11 -12.33%
S3 205.81 -19.49%

FAQ

What is the symbol for Ascendis Pharma A/S Stock and on which exchange is it traded?
The symbol for Ascendis Pharma A/S is ASND and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Ascendis Pharma A/S Stock?
Based on market data through Aug 10, 2026, StockInvest.us rates Ascendis Pharma A/S (ASND) as a Sell Candidate with a technical score of -2.73 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation. Since the Sell signal began on Aug 06, 2026, the price has risen 2.31%. The current 3-month trend forecast projects a rise of 12.41%.

How to buy Ascendis Pharma A/S Stock?
Ascendis Pharma A/S Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Ascendis Pharma A/S Stock.

What's the current price of Ascendis Pharma A/S Stock?
As of the end of day on the Aug 10, 2026, the price of an Ascendis Pharma A/S (ASND) share was $255.62.

What is the 52-week high and low for Ascendis Pharma A/S Stock?
The 52-week high for Ascendis Pharma A/S Stock is $281.79 and the 52-week low is $186.05.

What is the market capitalization of Ascendis Pharma A/S Stock?
As of the Aug 10, 2026, the market capitalization of Ascendis Pharma A/S is 15.877B.

When is the next earnings date for Ascendis Pharma A/S?
The upcoming earnings date for Ascendis Pharma A/S is Aug 13, 2026.
Click to get the best stock tips daily for free!
ABOUT ASCENDIS PHARMA A/S
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra...
GOLDEN STAR
Ticker Change Signal Date
GPOR
$158.45
6.03% Aug 06
FCX
$62.63
12.61% Jul 31
BIIB
$202.19
2.44% Jul 24
TSCO
$30.32
14.18% Jul 23
S
SW
$43.71
8.88% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE